Frequency and severity of COVID-19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine콜히친 또는 하이드록시클로로퀸으로 정기적으로 치료받는 다양한 류마티스 질환 환자의 COVID-19 빈도 및 중증도Article Published on 2022-07-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 진단, 치료법, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus analyzed anti-SARS-CoV-2 IgG Arthritis being Clinical data Colchicine collected Contact control group coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19-related symptom COVID-19-related symptoms described disease Famial Mediterranean fever Familial Familial Mediterranean fever FIVE HCQ healthy hospital Hospital admission Hospitalized household contact Hydroxychloroquine IgG Immunoglobulin Immunoglobulin G less Lupus lupus erythematosus Manifestations Mediterranean fever Musculoskeletal nucleocapsid occurred Odds ratio Patient positive prevention of COVID-19 respiratory rheumatic and musculoskeletal disease. rheumatic disease Rheumatoid rheumatoid arthritis seropositive subjects serum sample serum samples severe disease severity of COVID-19 subject syndrome systemic systemic lupus erythematosus the patient treated Treatment [DOI] 10.1002/jmv.27731 PMC 바로가기 [Article Type] Article
The naturally-derived alkaloids as a potential treatment for COVID-19: A scoping reviewCOVID-19의 잠재적 치료제로서의 천연 유래 알칼로이드: 범위 검토Review Published on 2022-07-012022-09-11 Journal: Phytotherapy research : PTR [Category] COVID19(2023년), SARS, 치료제, [키워드] activities acute respiratory syndrome coronavirus alkaloids Anti-inflammatory Antiviral applicability assessments berberine binding energy caused cephaeline clinical trial clinical trials Colchicine coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 database described Effects eligible Emetine Ergotamine high mortality rate homoharringtonine in silico in vitro Inflammatory marker inflammatory markers inhibit knowledge lycorine medicinal plant narciclasine natural product new treatment strategy observational studies papaverine pharmacological plant Potential treatment Protein target protein targets Quinine reduce respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 target proteins Therapeutic compounds Transmissibility treating COVID-19 variety was performed [DOI] 10.1002/ptr.7442 PMC 바로가기 [Article Type] Review
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trialRandomized Controlled Trial Published on 2022-06-302022-10-04 Journal: The British Journal of General Practice [Category] COVID19(2023년), SARS, 임상, [키워드] Adaptive platform trial Admission analysed Bayesian models benefit co-primary endpoint Colchicine colchicine group Community Comorbidity Complication COVID-19 COVID-19-related admission CrI criterion death determine hazard ratio Health higher risk hospital IMPROVE median time multi-arm multicentre Odds ratio Open-label other treatment participant positive primary analysis Primary Health Care Probability Prospective randomised randomised controlled trial reduce SARS-CoV-2 Shortness of breath time Time to recovery Treatment Trial usual care with COVID-19 [DOI] 10.3399/BJGP.2022.0083 PMC 바로가기 [Article Type] Randomized Controlled Trial
Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in AustraliaArticle Published on 2022-06-152022-10-04 Journal: PLoS ONE [Category] 신약개발, [키워드] 95%CI Analysis average change changes in Characteristics Colchicine Corticosteroid Corticosteroids COVID-19 COVID-19 pandemic cross-sectional Dispensing effective Evidence expected help Hydroxychloroquine increase increase in increases in Ivermectin limit media Medicine Medicines Other Pandemics Patient perceived benefit performed Practitioner Prevent quantified Regulatory sustained therapeutic understanding Vitamin D while [DOI] 10.1371/journal.pone.0269482 PMC 바로가기 [Article Type] Article
Efficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trialRandomized Controlled Trial Published on 2022-06-022022-10-04 Journal: Scientific Reports [Category] 바이오마커, 임상, 치료법, [키워드] Admission aggravate anti-inflammatory treatment applied Arm benefit clinical benefit Colchicine colchicine group colchicine treatment components CPAP Cytokine storm syndrome death develop dose Efficacy Endpoint EudraCT hospitalized patient hyperinflammation ICU admission in both groups intensive care Invasive mechanical ventilation investigator-initiated trial mechanical ventilation moderate Most patient Non-invasive observer-blinded occurred outcome outcome measure Patient patients with COVID-19 Pneumonia Primary outcome pulmonary disease Randomized randomized clinical trial Randomly receive Severe COVID-19 pneumonia standard care steroid study population Trial with COVID-19 [DOI] 10.1038/s41598-022-13424-6 PMC 바로가기 [Article Type] Randomized Controlled Trial
Clinical update on COVID-19 for the emergency and critical care clinician: Medical management응급 및 중환자 진료의를 위한 COVID-19에 대한 임상 업데이트: 의료 관리Review Published on 2022-06-012022-09-11 Journal: The American journal of emergency medicine [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] 2019 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Admitted Patient antagonists antivirals Aspirin Care caused Chloroquine clinical clinician Clinicians Colchicine concerning convalescent plasma coronavirus coronavirus disease Coronavirus-2019 COVID-19 Critical care demonstrated disease Emergency Famotidine help Hydroxychloroquine IMPROVE interleukin interleukin-6 introduced Ivermectin kinase inhibitors management mineral Minerals monoclonal antibodies morbidity and mortality outcomes Outpatient outpatients pandemic Patient patients progressed prophylactic anticoagulation provide Randomized respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Steroids Therapies therapy utility variety Vitamin vitamins with COVID-19 [DOI] 10.1016/j.ajem.2022.03.036 PMC 바로가기 [Article Type] Review
Recommendations for the Outpatient Drug Treatment of Patients With COVID-19Article Published on 2022-05-132022-11-15 Journal: Deutsches Ärzteblatt international [Category] 진단, [키워드] Acetylsalicylic acid carried Clinical efficacy clinically Colchicine college concerning conducted Consensus Course COVID-19 COVID-19 outpatient COVID-19 patient dose drug drug treatment early phase Elderly patient Evidence expected family general practitioner high risk Hospitalization in vitro Infection Ivermectin off-label offered Outpatient Patient patient selection physician Prevent primary care Prophylaxis Randomized controlled trial recommendation reduced Remdesivir response to vaccination retrieved risk risk factor severe disease course systemic steroids the disease treated Treatment treatment for COVID-19 Trial with COVID-19 [DOI] 10.3238/arztebl.m2022.0203 PMC 바로가기
Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trialsCOVID-19 환자에서 콜히친의 안전성과 효능: 무작위 대조 시험의 체계적인 검토 및 메타 분석Meta-Analysis Published on 2022-04-052022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI age all-cause mortality Analysis anti-inflammatory drug average average age C-reactive protein calculated carried clinical trial clinical trials Colchicine colchicine treatment COVID-19 COVID-19 patient COVID-19 patients COVID-19 severity CRP level CRP levels Cytokine storm D-dimer level D-dimer levels database Diseases effective Efficacy evaluate FIVE Google Scholar Gout inhibiting Interleukins Invasion mean difference mechanical ventilation Meta-analysis no significant difference Odds ratio Odds ratios outcome outcomes P-value p-values Patient random-effects model Randomized randomized control trial RCT RCTs receiving reduce Safety safety profile searched significantly standard care statistically significant systematic review the cytokine storm total population treat Treatment trials [DOI] 10.1371/journal.pone.0266245 PMC 바로가기 [Article Type] Meta-Analysis
Pharmacological treatment of COVID-19: an opinion paperCOVID-19의 약리학적 치료: 의견서Review Published on 2022-04-012022-09-11 Journal: Revista española de quimioterapia : publicación [Category] COVID19(2023년), SARS, 치료제, [키워드] adalimumab Anakinra approach AZD7442 Azithromycin Banlanivimab Baricitinib BRII-196 BRII-198 canakinumab Casirivimab Certolizumab Ciganilmab Colchicine college Committee convalescent convalescent plasma COVID-19 Critical Dexamethasone drug drugs effective Efficacy English Etanercept etesevimab Evusheld Favipiravir fluvoxamine Golimumab help Hydroxychloroquine Imdevinab immune response Immunotherapy indication infliximab itolizumab Ivermectin Lemilumab Lopinavir Lopinavir/ritonavir Medicines metformin molnupiravir offer Pandemia pandemic Paxlovid PF-07321332 physician precocity prevented Ravulizumab Remdesivir Ritonavir ruxolitinib sarilumab SARS-CoV-2 Scientific Committee Sotrovimab Spanish the vaccine therapeutic Tixagevimab Tocilizumab Tofacitinib Treatment Vaccine virus Vitamin Vitamin D [DOI] 10.37201/req/158.2021 PMC 바로가기 [Article Type] Review
Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammationReview Published on 2022-03-012023-07-08 Journal: Inflammation research : official journal of the Eu [Category] COVID19(2023년), [키워드] Colchicine COVID-19 IL-1β IL-6 NLRP3 inflammasome SARS-CoV-2 [DOI] 10.1007/s00011-022-01540-y PMC 바로가기 [Article Type] Review